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Myosin II is an ATPase motor protein essential for many cellular 
functions including cell migration[1] and division.[2] In nonmuscle 
cells, myosin modulates protrusions at the leading edge and 
promotes retraction at the trailing edge during migration,[3] while 
during cytokinesis, myosin is required for contraction of the 
cleavage furrow.[4] For nonmuscle myosin, these varied functions 
are regulated by phosphorylation of the associated myosin 
regulatory light chain (mRLC) protein at Ser19, which activates the 
myosin complex to promote myosin assembly, cell contractility, and 
stress fiber formation.[5] Upon phosphorylation of the mRLC at both 
Thr18 and Ser19, these activities are further enhanced.[ 6 ] The 
dramatic effects of phosphorylation can also be recapitulated in vitro. 
Specifically, myosin and the proteolytic derivative heavy 
meromyosin (HMM),[ 7 ] which contains only one-third of the C-
terminal myosin tail, exhibit low in vitro activities when associated 
with the nonphosphorylated mRLC. Phosphorylation of Ser19 
amplifies actin-activated ATPase activities 10 – 1000-fold[ 8 ] and 
leads to myosin-mediated actin translocation.[9] 
While myosin has been studied extensively for almost five 
decades, questions surrounding the dynamic interactions of the 
protein within live cells remain. Methods currently used to study 
myosin and modulate activity include gene deletions or siRNA-
mediated knockdown of gene expression,[3] overexpression of 
kinases that phosphorylate the mRLC,[ 10 ] and small molecule 
inhibitors of myosin,[ 11 ] mRLC kinases,[ 12 ] and myosin 
phosphatase.[13] While these methods have provided a wealth of 
valuable information about myosin, they do not enable studies of the 
spatial dynamics of myosin regulation because localized activation 
cannot be achieved. Additionally, genetic approaches provide 
imprecise temporal control over protein function, preventing real-
time studies of the protein. Thus, we sought to develop chemical 
tools to overcome these drawbacks and to complement the existing 
approaches by enabling direct and controlled myosin activation 
through the semisynthesis of a photoactivated mRLC. The light-
mediated activation is achieved by the incorporation of a photolabile 
protecting group, or “caging group,” onto the essential phosphate of 
pSer19 within the full-length mRLC. The caging group masks the 
phosphate functionality and renders the protein biologically inactive 
until irradiation removes the masking group and releases the active 
native phosphoprotein. By using light as the trigger for 
phosphorylation, this strategy offers a kinase-independent method to 
activate myosin with precise spatial and temporal resolution and 
enables researchers to obtain real-time information about the 
downstream effects of myosin phosphorylation within a complex 
network of interactions.[14] 
The 1-2-(nitrophenyl)ethyl (NPE) caging group has been 
employed for cellular applications because it is efficiently released, 
under biologically-compatible conditions, at 365 nm. Peptides and 
proteins containing NPE-caged phosphorylated amino acids have 
been successfully exploited for the study of many diverse 
systems.[15] Additionally, a general method for incorporating NPE-
caged thiophosphoamino acids, which, upon irradiation, function 
similarly to the corresponding phosphorylated species but with 
greater resistance to phosphatases, has been reported[16] and can be 
used for advancing studies of myosin. 
Herein we report the development of a chemical approach to 
investigate myosin function through the preparation of unnatural 
amino acid mutants of the mRLC. We present an efficient 
semisynthesis of full-length mRLC through expressed protein 
ligation for the site-specific incorporation of phosphorylation at 
Ser19 (pSer19) and Thr18 (pThr18) and the genesis of caged 
phosphoserine (cpSer) and caged thiophosphoserine (c(S)pSer) at 
position 19. Caging of pSer19 eliminates myosin and HMM 
activities, and irradiation releases the native phospho-mRLC to 
restore activity to nearly native phosphorylated levels (Figure 1). 
Microinjection of myosin exchanged with the caged protein into live 
cells and subsequent irradiation releases the phosphoprotein within 
cells. This tool is poised to facilitate future investigations of the 
downstream effects of myosin activation. 
 
Figure 1. Installation of NPE-caged pSer19 into the mRLC is 
achieved by expressed protein ligation. The caging group masks the 
phosphate necessary for myosin activation until irradiation releases it 
to generate the native phosphoprotein and restore activity. Image was 
modified from Protein Data Bank file 1WDC. 
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Semisynthesis of the mRLC was achieved through native 
chemical ligation (NCL)[17] between a synthetic peptide thioester 
corresponding to the N-terminal region of the mRLC (residues 1 – 
23) and a recombinant protein fragment comprising the remaining 
C-terminal residues (residues 25 – 171) and a Met24Cys mutation 
(Scheme 1). To probe the effects of phosphorylation at discrete sites 
of the mRLC, the protein was synthesized with no phosphorylation 
(1) and with pSer19 (2), pThr18 (3), pThr18 pSer19 (4), cpSer19 (5), 
and c(S)pSer19 (6).  
 
 
 
Scheme 1. Semisynthesis of the full-length mRLC. The C-terminal 
portion of the mRLC is expressed heterologously in E. coli. TEV 
proteolysis releases GST and reveals the N-terminal cysteine, which 
reacts in the NCL with the synthetic peptide thioester to generate the 
full-length mRLC.   
Table 1. Peptide thioester derivatives used in the semisynthesis of 
mRLC.[a] 
 
FLAG-mRLC(1-23): DYKDDDDK-SSKKAKTKTTKKRPQRA XY NVFA 
Entry Derivative R1 R2 
1 NonP OH OH 
2 pSer19 OH OPO32- 
3 pThr18 OPO32- OH 
4 pThr18 pSer19 OPO32- OPO32- 
5 cpSer19 OH 
 
 
6 c(S)pSer19 OH 
 
[a] Peptides were synthesized by Fmoc-based solid phase peptide 
synthesis as C-terminal thioesters.  
The peptide thioesters containing the phosphorylated or caged 
phosphorylated derivatives were synthesized through Fmoc-based 
solid phase peptide synthesis (Tables 1, S1).  The C-terminal portion 
of the protein was expressed in E. coli as a fusion to glutathione S-
transferase (GST) to enhance expression and aid purification.  Next, 
tobacco etch virus (TEV) proteolysis released GST to expose the N-
terminal cysteine needed for the ligation. The peptide and protein 
fragments were combined in the NCL reaction, which efficiently 
afforded milligram quantities of the full-length mRLC at about 75% 
conversion relative to the unligated protein (Figure S1). N-terminal 
FLAG epitope and C-terminal hexahistidine tags facilitated isolation 
of the semisynthetic product from unligated protein and excess 
peptide, respectively. After purification, the mass of the protein was 
confirmed by MALDI analysis.  
We then characterized the ability of the semisynthetic protein to 
regulate in vitro myosin activity and to enable myosin 
photoactivation. Semisynthetic mRLC was exchanged for the native 
mRLC in chicken gizzard smooth muscle HMM and myosin (Figure 
S2) and then tested in ATPase[18] and sliding filament assays.[19] We 
first focused on the ATPase assays, and due to greater tractability in 
solution, HMM, rather than myosin, was used.[7] Similar to HMM 
with the native nonphosphorylated mRLC, the actin-activated 
ATPase activity of HMM exchanged with 1 was negligible (Figure 
2a). HMM exchanged with 2 displayed activity similar to that of 
HMM phosphorylated by myosin light chain kinase (MLCK) (0.80 
± 0.07 and 0.98 ± 0.13 s-1, respectively). These experiments 
establish that the semisynthetic mRLC fully and faithfully regulates 
HMM enzymatic activity. Additionally, introduction of the FLAG 
epitope and hexahistidine tags do not influence function.  
In addition to Ser19, the mRLC can also be phosphorylated at 
Thr18.[20] Studies of Thr18 phosphorylation alone have relied on a 
Ser19Ala mutation because Ser19 is normally phosphorylated 
before Thr18.[ 21 ] Moreover, mRLC diphosphorylation has been 
observed in vitro and in cells, but complete in vitro phosphorylation 
requires high concentrations of MLCK.[20] Our semisynthetic 
approach provides, for the first time, convenient access to 
homogenously phosphorylated proteins, allowing the effects of 
defined phosphorylation to be examined without the need for 
mutations at positions 18 or 19 of the mRLC. ATPase assays of 
HMM exchanged with 3 showed that phosphorylation of Thr18 
moderately increases activity to 0.18 ± 0.03 s-1, whereas 
phosphorylation at both Thr18 and Ser19 (4) generates even greater 
activity (1.16 ± 0.11 s-1) than pSer19 alone (Figure 2a). These trends 
are consistent with previous studies on the effects of kinase-
mediated Thr18 phosphorylation and diphosphorylation.[21] 
 
 
Figure 2. Actin-activated ATPase activities of HMM. The values are 
the means ± SD of at least three trials. NonP, nonphosphorylated; P, 
phosphorylated by MLCK. a) Actin-activated ATPase activity of HMM 
with native (gray bars) and noncaged semisynthetic derivatives (black 
bars). b) Actin-activated ATPase activity of HMM with semisynthetic 
noncaged derivatives (black bars) and caged derivatives (open bars) 
before (-UV) and after (+UV) irradiation at 365 nm for 90 s.  
Next, we investigated the ability to photoactivate the protein. 
We first used RP-HPLC analysis to examine the kinetics of NPE 
removal after irradiation of the caged peptide on a DNA 
transilluminator (365 nm) (Figure S3). The duration of uncaging 
was optimized according to this analysis, which demonstrated that 
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irradiation for 90 s released about 70% of the free phosphopeptide. 
Western blot analysis of the full-length caged proteins (5 and 6) 
with an anti-pSer19 mRLC antibody confirmed that the phospho- 
and thiophosphoproteins were generated upon irradiation (Figure 
S4).  
Following exchange of caged mRLCs 5 and 6 into HMM, actin-
activated ATPase assays demonstrated that the activity of the caged 
proteins was low and mimicked that of nonphosphorylated mRLC 1 
(Figure 2b). Irradiation on a transilluminator at 365 nm for 90 s 
increased activity about 20-fold to levels near that of HMM 
exchanged with the semisynthetic pSer19 mRLC (2). Importantly, 
the caged proteins completely suppress HMM ATPase activity, 
indicating that the caging group is sufficient to maintain the 
inhibited state of the protein. The activities following uncaging 
(0.48 ± 0.04 and 0.43 ± 0.05 s-1 for 5 and 6, respectively) are 
consistent with restoration of about 60% activity compared to that of 
HMM with semisynthetic pSer19 mRLC 2 and lie within the range 
expected based on the HPLC peptide uncaging analysis. Thus, 
irradiation enables direct control over the release of the 
phosphorylated mRLC and, correspondingly, over HMM activation. 
 
 
Figure 3. In vitro myosin sliding filament assays. a) The mean 
velocities ± SD of at least 45 actin filaments during incubation with 
native myosin (gray bars) and myosin exchanged with the noncaged 
semisynthetic (black bars) and caged semisynthetic (open bars) 
mRLCs. NMO, no motility observed; NonP, nonphosphorylated; P, 
phosphorylated by MLCK. b) Actin filament paths from a 
representative field before (-UV) and after (+UV) 90 s irradiation of 
myosin exchanged with cpSer19 mRLC 5. 
 
 
To further characterize the semisynthetic proteins and the caging 
system, we performed sliding filament assays, which assess the 
force-generating ability of myosin. In this assay, we measure the 
velocities of fluorescently-labeled actin filaments propelled by 
myosin bound to a nitrocellulose-coated glass coverslip. Myosin 
was used in these assays because it produced more consistent 
filament movement than HMM. Nonphosphorylated myosin and 
myosin exchanged with 1 did not move the actin filaments, but both 
MLCK-phosphorylated myosin and myosin exchanged with 2 led to 
significant movement with velocities around 0.9 μm s-1 (Figure 3a). 
Each phosphorylated semisynthetic derivative generated filament 
movement at velocities between 0.7 and 1.0 µm s-1. A one-way 
ANOVA followed by Tukey’s post-hoc test indicated that the 
differences among myosin exchanged with 2, 3, and 4 are 
statistically significant, with all comparisons yielding p < 0.0001 
(Figure 3a). The velocities follow the relative trends observed in the 
ATPase assays with pThr18 producing the smallest and pThr18 
pSer19 generating the greatest velocities. These results are 
consistent with a previous study in which myosin with an mRLC 
phosphorylated at Thr18 and containing a Ser19Ala mutation 
generated slightly lower filament velocities than the pSer19 and 
pThr18 pSer19 derivatives.[21b] However, our results also indicate 
differences between phosphorylation at Ser19 and double 
phosphorylation (pThr18 pSer19), which have not been previously 
reported. 
With both caged proteins 5 and 6, negligible filament movement 
was observed before irradiation (Figures 3a, 3b, S5). In contrast, 
irradiation of myosin prior to the assay generated significant 
filament movement with velocities comparable to those observed 
with MLCK-phosphorylated myosin or myosin exchanged with the 
semisynthetic pSer19 mRLC. Although about 60% of the HMM 
ATPase activity was achieved after uncaging, the sliding filament 
velocities were fully restored following irradiation. Previous studies 
have shown that while steady-state ATPase activities increase 
proportionally with the degree of myosin phosphorylation,[22] sliding 
filament velocities follow a nonlinear trend and reach a maximal 
value even in the presence of nonphosphorylated myosin.[23] 
The in vitro studies establish that caging of pSer19 provides 
effective photochemical control over myosin activity. Finally, in 
order to test these chemical tools in live cells, we microinjected the 
caged mRLC into COS7 cells and investigated uncaging in situ. 
Initially, the caged thiophosphorylated mRLC 6 was used to 
minimize potential complicating effects from cellular phosphatases. 
Additionally, because incorporation of the injected mRLC into 
endogenous myosin complexes was slow, gizzard smooth muscle 
myosin exchanged with the caged protein was prepared in vitro and 
microinjected. Following irradiation of the injected cells on a 
transilluminator, the cells were fixed, stained with an anti-pSer19 
mRLC antibody, and analyzed by immunofluorescence microscopy. 
The signal from the anti-pSer19 mRLC antibody was significantly 
higher following uncaging compared to injected cells that had not 
been irradiated (Figures 4, S6). These studies indicate that the 
thiophosphorylated protein can be readily and reproducibly 
generated within a cellular system and represent the foundation for 
future investigations of the real-time effects of myosin 
phosphorylation within living cells.   
  
 
Figure 4. Cells injected with myosin exchanged with 6 and Texas 
Red-labeled dextran marker before (Caged) or after (Uncaged) 
irradiation.  The cells were fixed and stained with an antibody specific 
for pSer19 mRLC. Scale bar: 10 µm. 
In summary, the semisynthetic approach provides convenient 
access to milligram quantities of various phosphorylated and caged 
phosphorylated mRLC derivatives, which facilitate studies of 
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individual sites of phosphorylation. This general method can be 
readily adapted for the incorporation of other unnatural elements 
into the N-terminal domain of the mRLC. Additionally, the caged 
protein enables precise photocontrol over HMM and myosin activity. 
Uncaging efficiently furnishes the phospho- and 
thiophosphoproteins that appropriately regulate HMM and myosin 
activity. The in vitro characterization of the semisynthetic protein 
and the cellular uncaging experiments provide the basis for 
subsequent studies of myosin phosphorylation within a cellular 
environment. For instance, this system could be used to further 
address effects of myosin phosphorylation on stress fiber and focal 
adhesion formation. Offering the unique ability to activate myosin 
with precise spatial and temporal resolution, this approach promises 
to help unravel the complex role of the protein within the cell.  
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Table S1.  Characterization of Peptide Thioesters 
 
 
 
 
[a] The data were collected by positive ion electrospray ionization mass spectrometry.  [b] Retention times were 
obtained from reverse phase HPLC analytical runs (YMC C18, ODS-A, 5 µm, 4.6  250 mm) using the following 
method:  5% acetonitrile in water with 0.1% TFA for 5 min, followed by a linear gradient of 5-95% acetonitrile in 
water with 0.1% TFA over 30 min at 1 mL min-1. 
 
 
Peptide 
Thioester Sequence Molecular Formula 
Molecular 
Weight 
Calculated
[MH5]5+ 
Calculated 
[MH5]5+ 
Found[a] 
HPLC 
(tR)[b] 
Non- 
phosphorylated 
Ac-DYKDDDDKSSKKAKTKT 
TKKRPQRATSNVFA-COSBn C160H261N47O52S 3704.89 742.0 742.0 21.3 
pSer19 Ac-DYKDDDDKSSKKAKTKT TKKRPQRAT pS NVFA-COSBn C160H262N47O55PS 3784.86 758.0 758.0 21.0 
pThr18 Ac-DYKDDDDKSSKKAKTKT TKKRPQRA pT SNVFA-COSBn C160H262N47O55PS 3784.86 758.0 758.0 20.9 
pThr18 pSer19 Ac-DYKDDDDKSSKKAKTKT TKKRPQRA pTpS NVFA-COSBn C160H263N47O58P2S 3864.83 774.0 774.0 20.6 
Caged pSer19 Ac-DYKDDDDKSSKKAKTKT TKKRPQRAT cpS NVFA-COSBn C168H269N48O57PS 3933.91 787.8 787.9 22.1 
Caged 
Thiophospho-
Ser19 
Ac-DYKDDDDKSSKKAKTKT 
TKKRPQRAT cp(S)S NVFA-
COSBn 
C168H269N48O56PS2 3949.89 791.0 791.1 22.6 
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Figure S1.  Synthesis and Purification of Semisynthetic mRLC.  Coomassie-stained 12% SDS PAGE gel of 
the mRLC semisynthesis showing GST-TEV-mRLC-His6 after purification by glutathione resin (lane 1), the TEV 
cleavage of GST-TEV-mRLC-His6 (lane 2), the crude native chemical ligation reaction (lane 3), the protein purified 
by Ni-NTA affinity chromatography (lane 4), and the final semisynthetic mRLC after FLAG-affinity purification 
(lane 5).   
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Figure S2.  Exchange of semisynthetic mRLC into HMM and Myosin.  a) 12% SDS PAGE gel of a 
representative HMM exchange showing unexchanged HMM (lane 1), caged semisynthetic mRLC (lane 2), HMM 
purified after the first exchange (lane 3), and HMM purified after the second exchange (lane 4).  b) 12% SDS 
PAGE gel of a representative myosin exchange showing native myosin (lane 1), caged semisynthetic mRLC (lane 
2), myosin after the first exchange (lane 3), and myosin after the second exchange (lane 4).  For both HMM and 
myosin, two consecutive exchanges leads to over 95% incorporation of the semisynthetic mRLC.  Due to the 
addition of the N- and C-terminal tags, the mobility of the semisynthetic mRLC, compared to the native mRLC, is 
reduced on the SDS PAGE gel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Essential light chain 
Semisynthetic mRLC 
Native mRLC 
Essential light chain 
1       2       3       4 kDa 
 
 
75 
 
50 
 
37 
 
 
 
25 
 
20 
 
 
 
15 
HMM 
a) 
Myosin heavy chain 
kDa 
 
 
 
75 
 
50 
 
37 
 
 
 
 
25 
 
20 
 
 
 
 
15 
Semisynthetic mRLC 
Native mRLC 
1       2       3       4 b) 
S5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3.  Uncaging time course of caged pSer19 mRLC peptide.  A solution of the caged pSer19-mRLC 
peptide acid (86 μM) in 10 mM HEPES (pH 7.1), 5 mM DTT, and 0.8 μM inosine was irradiated on a 
transilluminator (365 nm) for the indicated times in a quartz vessel (1 mm pathlength).  The peptide species were 
quantified by analytical RP-HPLC monitored at 228 nm.  The areas of the caged and uncaged peptide peaks 
relative to the area of the inosine peak were determined.  The percent of each species relative to the initial 
amount of the caged peptide is plotted against the duration of irradiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4.  Uncaging of Caged Phosphoserine19 and Caged Thiophosphoserine19 mRLC.  Western blot 
probed with an antibody specific for the pSer19 mRLC showing the caged pSer19 (5) and caged 
thiophosphoserine19 (6) mRLCs with no irradiation (lanes 1 and 3, respectively) and after 90 s irradiation on a 
transilluminator (lanes 2 and 4, respectively). 
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Figure S5.  Actin Filament Paths with the Caged Thiophosphoserine19 mRLC.  Filament paths in the sliding 
filament assay with non-irradiated (-UV) and irradiated (+UV) myosin exchanged with caged thiophosphoserine19 
mRLC (6).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S6.  Cellular Uncaging Assessed by pSer19 mRLC Antibody Staining.  COS-7 cells were injected with 
a solution of 6 and Texas Red dextran, exposed to UV irradiation (2 min on a transilluminator) if indicated, fixed, 
permeabilized, and stained for pSer19 mRLC. The intensity of anti-pSer19 mRLC antibody staining in individual 
cells is plotted against the dextran fluorescence intensity, which corresponds to the amount of protein that was 
injected.   
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Materials and Methods 
 
Abbreviations 
 
ATP: adenosine triphosphate; BSA: bovine serum albumin; CIP: calf intestinal phosphatase; DCM: 
dichloromethane; DIPEA: N,N-diisopropylethylamine; DMF: N,N-dimethylformamide; DTT: 
dithiothreitol; EDTA: ethylenediaminetetraacetic acid; EGTA: glycol-bis(2-aminoethylether)-N,N,N′,N′-
tetraacetic acid; ESI-MS: electrospray ionization mass spectrometry; Fmoc: 9-
fluorenylmethoxycarbonyl; GST: glutathione-S-transferase; HATU: O-(7-azabenzotriazole-1-yl)-
N,N,N′,N′-tetramethyluronium hexafluorophosphate; HBTU: O-benzotriazole-1-yl-N,N,N′,N′-
tetramethyluronium hexafluorophosphate; HMM: heavy meromyosin; HOAt: 1-hydroxy-7-
azabenzotriazole; HOBt: 1-hydroxy-benzotriazole; HPLC: high performance liquid chromatography; 
IPTG: isopropyl-1-thio-β-D-galactopyranoside; LB: Luria-Bertani; MALDI: matrix-assisted laser 
desorption ionization; MOPS: 3-(N-morpholino)propanesulfonic acid; MWCO: molecular weight cut 
off; NTA: nitrilotriacetic acid; PBS: phosphate-buffered saline; PyBOP: benzotriazole-1-yl-oxy-tris-
pyrrolidino-phosphonium hexafluorophosphate; SDS: sodium dodecyl sulfate; SDS PAGE: sodium 
dodecyl sulfate polyacrylamide gel electrophoresis; TBS: tris-buffered saline; TBST: tris-buffered saline 
with Tween-20; TFA: trifluoroacetic acid; TEV: tobacco etch virus; TIRF: total internal reflection 
fluorescence; TNBS: 2,4,6-trinitrobenzene sulfonic acid; Tris: tris(hydroxymethyl)aminomethane; 
TRITC: tetramethyl rhodamine isothiocyanate. 
 
Materials 
 
Unless otherwise noted, all reagents and solvents for peptide synthesis were obtained commercially from 
Sigma Aldrich and used without further purification.  Anhydrous DCM was distilled from calcium 
hydride.  NovaSyn TGT resin, Fmoc-amino acids, PyBOP, HATU, HOAt, HBTU, and HOBt were 
obtained from Novabiochem.  BL-21 Codon Plus RP cells were obtained from Agilent Technologies, 
Protease Inhibitor Cocktail Set III was from Calbiochem, Glutathione Sepharose 4 Fast Flow was 
obtained from GE Healthcare, Ni-NTA affinity resin was from Qiagen, and anti-FLAG M2 agarose was 
obtained from Sigma Aldrich.  Amicon Ultra centrifugal filter devices were obtained from Millipore, 
and Slide-A-Lyzer dialysis cassettes, goat anti-rabbit IgG + IgM (H+L) alkaline phosphatase 2° 
antibody, and 1-Step NBT/BCIP substrate for alkaline phosphatase were from Thermo Fisher Scientific.  
Rabbit anti-pSer19 mRLC antibodies for Western blots and cellular studies were obtained from 
GeneTex and GenScript, respectively.  The Alexa Fluor 647 goat anti-rabbit antibody was purchased 
from Invitrogen.  Chicken gizzards and rabbit skeletal muscle acetone powder were purchased from 
PelFreeze. 
 
Peptide Synthesis  
 
All peptides were synthesized by solid phase peptide synthesis either manually or on an Applied 
Biosystems 431A peptide synthesizer using Fmoc-protected amino acids.  Each peptide synthesis was 
performed on a 0.04 mmol scale using a 0.2 mmol/g loading Fmoc-Ala-NovaSyn TGT resin, which 
installed alanine as the C-terminal residue for all peptides.  The N-terminus was acetylated by reaction 
with acetic anhydride and pyridine in DMF (20 equivalents each). 
S8 
 
The procedure for the manual synthesis follows.  The resin (0.2 g, 0.04 mmol) was swelled in DCM (5 
mL) for 5 min and then in DMF (5 mL) for 5 min.  The resin was incubated (5  5 min) with 5 mL 20% 
4-methylpiperidine in DMF and then washed with DMF (5 mL, 5  1 min).  The next Fmoc-amino acid 
(0.24 mmol) dissolved in DMF (5 mL) with PyBOP (0.12 g, 0.24 mmol) was added.  DIPEA (84 µl, 
0.48 mmol) was added, and the reaction was allowed to proceed for at least 45 min.  The success of 
coupling was evaluated by a TNBS test, and if no beads turned red, the procedure was repeated using the 
next amino acid.  Phosphopeptides were synthesized by employing commercially available Fmoc-
Thr(PO(OBzl)-OH)-OH or Fmoc-Ser(PO(OBzl)-OH)-OH.  The caged residues N-α-Fmoc-phospho(1-
nitrophenylethyl-2-cyanoethyl)-L-serine and N-α-Fmoc-phosphorothioyl(1-nitrophenylethyl-2-
cyanoethyl)-L-serine were synthesized according to Rothman, et al.[1] and Aemissegger, et al.,[2] 
respectively.  These residues (0.08 mmol) were coupled with HATU (0.08 mmol), HOAt (0.08 mmol), 
and 2,4,6-collidine (0.10 mmol) to prevent -elimination of the phosphotriester. 
Peptides were prepared by automated solid phase peptide synthesis on an Applied Biosystems 431A 
synthesizer employing standard Fmoc-protected amino acids (4 equivalents relative to resin loading per 
coupling), HOBt and HBTU coupling reagents, and 4-methylpiperidine deprotections.  Double 
couplings and acyl capping were performed.  On the automated synthesizer, Ser1 and Ser2 were coupled 
as the corresponding pseudoproline dipeptide Fmoc-Ser(tBu)-Ser(ΨMe,Mepro)-OH, and Lys8 and Thr9 
were incorporated using Fmoc-Lys(Boc)-Thr(ΨMe,Mepro)-OH.  These pseudoproline dipeptides 
improved the yields and purities of the final peptides.  
 
Peptide Thioester Synthesis 
 
The N-terminal acyl-capped peptides (0.04 mmol) were cleaved from the TGT resin without side chain 
deprotection in 0.5% TFA in DCM for 2 h.  The solution was evaporated to about 1 mL, and the peptide 
was precipitated with hexanes.  The solution was rotovapped, and the peptide was dried in vacuo.  The 
peptide was dissolved in freshly distilled DCM (12 mL) under argon.  HATU (0.061 g, 0.16 mmol), 
HOAt (0.022 g, 0.16 mmol), benzyl mercaptan (94 μL, 0.8 mmol), and 2,4,6-collidine (42 µl, 0.32 
mmol) were added, and the reaction was stirred at RT under argon for 4 h.  Under these conditions, 
epimerization of the C-terminal alanine was minimized (to ~6% based on model studies).  The reaction 
was then rotovapped to dryness, and the side chain protecting groups were removed in 10 mL of 95% 
TFA with 2.5% triisopropyl silane and 2.5% H2O for 2 h.  The TFA was evaporated, and the peptide 
was triturated with cold diethyl ether (40 mL, 3).  Peptides were purified by reverse phase HPLC with 
a Waters 600 automated control module on a YMC C18 semi-preparative column (YMC-Pack ODS-A, 5 
µm, 20  250 mm) eluting with acetonitrile/water containing 0.1% TFA.  For detection, a Waters 2487 
dual wavelength absorbance detector was used to record at 228 nm and 280 nm.  HPLC conditions were 
5% acetonitrile in water with 0.1% TFA for 5 min followed by a linear gradient from 20% to 50% 
acetonitrile in water with 0.1% TFA over 45 min.  Following lyophilization, correct mass was validated 
by ESI-MS on a Mariner electrospray mass spectrometer (PerSpective Biosystems) (Table S1).  Purity 
was confirmed by analytical HPLC with a Beckman Ultrasphere C18 reverse phase column (YMC ODS-
A, 5 µm, 4.6  250 mm). 
  
Cloning 
 
To generate the GST-mRLC protein fusion, the C-terminal portion of the mRLC was subcloned into the 
pGEX-4T-2 vector.  The gene fragment encoding mRLC(25 – 171) was amplified by polymerase chain 
S9 
 
reaction from a vector containing the full mRLC gene (GenBank Accession AK002885).  The forward 
primer for PCR encoded a 5′ EcoRI restriction site, followed by the TEV protease cleavage sequence 
(ENLYFQ) and the Met24Cys mutation, and the reverse primer was used to encode a C-terminal 
hexahistidine tag and 3′ NotI restriction site. The sequences of the primers used for PCR are given 
below: 
 
Forward primer:    
5′-GCCGGAATTCGTGAGAACCTGTATTTCCAGTGCTTTGACCAGTCCCAGATC-3΄ 
 
Reverse Primer:   
5΄-GCGAAAGACAAAGATGACCATCACCATCACCATCACTAGGCGGCCGCAAAAGG 
GGGC-3΄ 
 
The PCR amplicons were digested with EcoRI and NotI and ligated into the pGEX-4T-2 vector, which 
had been digested with EcoRI and NotI and treated with CIP.  The ligated plasmid was transformed into 
DH5α cells and grown on LB plates containing carbenicillin (50 μg/mL). 
 
mRLC Expression 
 
The pGEX-mRLC plasmid was transformed into BL-21 Codon Plus RP cells, and the bacteria were 
grown on LB plates containing carbenicillin (50 μg/mL) and chloramphenicol (30 μg/mL).  A single 
colony was selected and grown in LB media (5 mL) supplemented with carbenicillin (50 µg/mL) and 
chloramphenicol (30 µg/mL).  This starter culture was used to inoculate a 1 L culture, which was 
incubated in a shaker at 225 rpm and 37 °C until an OD of ~0.6 at 600 nm was reached.  The culture was 
cooled to 16 °C, and IPTG was added to 0.2 mM to induce protein expression.  The culture was 
incubated overnight at 16 °C with shaking.  The next day, the cells were harvested by centrifugation, and 
the cell pellets were stored at -80 °C until use. 
 
Isolation and Purification of GST-mRLC 
 
The cell pellet was thawed on ice and brought up in 40 mL of PBS (150 mM NaCl, 10 mM phosphate, 
pH 7.7) containing 1 mg/mL lysozyme, 1 mM DTT, and 1 µL/mL Protease Inhibitor Cocktail Set III 
(100 µM AEBSF, 80 nM Aprotinin, 5 µM Bestatin, 1.5 µM E-64, 2 µM Leupeptin, 1 µM Pepstatin A) 
for each liter of cells harvested.  The cells were incubated on ice for 20 min and then sonnicated on ice 
at 40% amplitude, 1 s on/1 s off for 45 s with a Sonics Vibra Cell sonnicator.  Cell debris were pelleted 
at 90,000 rpm for 1 h at 4 °C, and the lysate was passed through a 0.2 µm filter.  Glutathione Sepharose 
4 Fast Flow (3 mL) was incubated with the cell lysate for 1.5 h at 4 °C.  The resin was isolated with a 
brief centrifugation and washed with 120 mL PBS at 4 °C.  The protein was eluted in four 3-mL 
fractions with buffer containing 10 mM reduced glutathione and 2 µL/mL Protease Inhibitor Cocktail 
Set III in 50 mM Tris, pH 8.0.  The protein was dialyzed in a 3,500 MWCO Slide-A-Lyzer dialysis 
cassette against PBS (3  2 L).  Protein concentration was determined through a BioRad assay with BSA 
as a standard.   
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TEV Cleavage 
 
TEV cleavage was performed by incubating the GST-mRLC protein (1.6 mg/mL) with TEV protease in 
buffer containing 50 mM Tris, pH 8.0, 0.5 mM EDTA, and 5 mM β-mercaptoethanol for 3.5 h at 30 °C 
and then overnight at 4 °C.  SDS PAGE confirmed complete proteolytic cleavage.   
 
Native Chemical Ligation 
 
The TEV-cleaved protein (NH2-Cys-mRLC(25-171)-His6) was concentrated to 14 mg/mL with an 
Amicon Ultra centrifugal filter device (MWCO 3,000).  Native chemical ligation reactions were 
performed by combining the thioester peptide (1.2 mM) with the TEV-cleaved protein (0.8 mM) in a 
buffer containing 150 mM sodium 2-mercaptoethanesulfonate and 50 mM Tris (pH 8.0).  The reactions 
were incubated for 18 h at RT.  The mixture was then diluted to 2 mg/mL and dialyzed against PBS (3  
2 L) in a Slide-A-Lyzer dialysis cassette (3,500 MWCO) to remove the thiol additives. 
 
Purification of Semisynthetic mRLC 
 
The ligation mixture was purified from excess peptide using Ni-NTA affinity chromatography.  The 
crude ligation was incubated with 2 mL Ni-NTA resin in PBS (25 mM NaH2PO4, 25 mM Na2HPO4, 300 
mM NaCl, pH 7.9) containing 5 mM imidazole.  After 1 h at 4 °C, the resin was collected and washed 
with 120 mL PBS containing 5 mM imidazole.  The protein was eluted with 12 mL of PBS containing 
300 mM imidazole and dialyzed against TBS (50 mM Tris, 200 mM NaCl, pH 7.5, 3  2 L).  The 
unligated protein was subsequently removed from the FLAG epitope-tagged ligation product using anti-
FLAG M2 agarose.  After incubating the protein with the resin in TBS for 1 h at 4 °C with gentle 
agitation, the resin was washed with 120 mL TBS.  The protein was eluted in 1-mL fractions with 0.1 M 
glycine (pH 3.5) into 50 μL of a solution of 1 M Tris (pH 7.8) and 0.8 M NaCl.  The purification was 
repeated using the flow through to recover unbound protein.  The pooled elutions from each purification 
were dialyzed into PBS.   
 
MALDI Analysis 
 
Mass analysis of the purified semisynthetic protein was obtained on a Voyager DESTR MALDI by the 
MIT Biopolymers Laboratory.  For semisynthetic nonphosphorylated mRLC 1: Expected [MH]+: 
21479.8; Found [MH]+: 21482.4. 
 
Proteins for ATPase and Sliding Filament Assays 
 
Myosin was isolated from chicken gizzards according to Ikebe and Hartshorne.[3]  HMM was generated 
by myosin proteolysis according to Ikebe and Hartshorne using Staphylococus aureus V8 protease, 
except that a GE Healthcare Superdex 200 HiLoad (16/60) size exclusion chromatography column was 
used for purification.[4]  Myosin light chain kinase was purified from chicken gizzards according to 
Ikebe, et al.,[5] and actin was purified from rabbit skeletal muscle acetone powder following protocols by 
Pardee and Spudich.[6] 
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Myosin and HMM Exchange 
 
The semisynthetic mRLC was exchanged into smooth muscle myosin according to modified procedures 
by Sherwood, et al.[7] and Ikebe, et al.[8]  Myosin (0.5 mg/mL) in exchange buffer (0.6 M NaCl, 20 mM 
sodium phosphate (pH 7.5), 10 mM DTT, 5 mM EDTA, 1 mM EGTA, and 5 mM ATP) was incubated 
for 30 min at 42 °C with about 5 molar equivalents of the semisynthetic mRLC.  After cooling on ice, 
MgCl2 was added to 20 mM.  To remove excess light chains, the myosin was precipitated by overnight 
dialysis into 15 mM Tris (pH 7.5), 10 mM MgCl2, and 1 mM DTT.  The pellet was collected by 
centrifugation and washed with dialysis buffer.  The pelleted protein was dissolved in the exchange 
buffer, and the protein was subjected to a second exchange to increase incorporation of the 
semisynthetic protein to at least 90%. 
 
The conditions for exchange into HMM (0.5 M NaCl, 20 mM sodium phosphate (pH 7.5), 10 mM DTT, 
5 mM EDTA, 1 mM EGTA, and 1 mM ATP) were modified from Ellison, et al.[9]  The HMM was 
incubated with a 5-fold excess of the semisynthetic mRLC at 42 °C for 30 min.  After cooling on ice, 
MgCl2 was added to 20 mM, and the excess light chains were purified from HMM through size 
exclusion chromatography on a GE Healthcare Superdex 200 (10/300 GL) column equilibrated in 30 
mM Tris (pH 7.5), 300 mM NaCl, 1 mM MgCl2, and 0.5 mM DTT.  Fractions containing HMM were 
pooled and concentrated in a 50,000 MWCO centrifugal filter unit, and the exchange was repeated.  
 
HMM Phosphorylation by Myosin Light Chain Kinase 
 
HMM was phosphorylated though a modified protocol from Ellison, et al.[9]  HMM (0.5 mg/mL in 15 
mM Tris (pH 7.4), 50 mM NaCl, 2.5 mM MgCl2, and 3.5 mM CaCl2) was incubated with ATP (1.4 
mM), myosin light chain kinase (30 µg/mL), and calmodulin (4 µg/mL) for 1 h at RT and then overnight 
at 4 °C.  
 
Uncaging 
 
Myosin or HMM exchanged with the caged semisynthetic protein in the appropriate assay buffer 
supplemented with 5 mM DTT was irradiated in a quartz vessel with a 1 mm pathlength on a UVP High 
Performance Ultraviolet Transilluminator with light centered at 365 nm (7330 μW/cm2) for 90 s. 
 
Western Blots 
 
Standard SDS PAGE on a 12% polyacrylamide gel was performed, and the proteins were transferred to 
a nitrocellulose membrane at 100 V for 1 h.  The blot was blocked with 5% BSA in TBST (TBS with 
0.05% Tween 20) overnight at 4 °C and then incubated with a rabbit anti-pSer19 mRLC antibody 
(1/1000 dilution) in 3% BSA in TBST for 2 h at RT.  The blot was washed in TBST (5  5 min) and 
incubated with a goat anti-rabbit IgG + IgM (H+L) alkaline phosphatase 2° antibody in TBST (1/5000 
dilution) for 1 h at RT.  The blot was then washed with TBST (3  5 min) and TBS (1  5 min) and 
developed with 1-Step NBT/BCIP substrate for alkaline phosphatase.   
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ATPase Assays 
 
The actin-activated ATPase activity of HMM was determined by measuring the inorganic phosphate 
released over 30 min.[10]  Assay conditions were modified from Ikebe and Hartshorne.[4]  HMM (0.1-0.2 
mg/mL) in 30 mM Tris (pH 7.5), 2.5 mM MgCl2, 20 mM KCl, 0.1 mM EGTA, and 1 mM DTT was 
incubated at 25 °C with actin (24 µM) in a final volume of 150 µL.  All protein used in the assay was 
dialyzed into the assay buffer prior to the assay.  The assay was initiated by the addition of ATP to 1 
mM.  For each time point, 30 µL of the myosin solution was added to 30 µL of the stop solution (60 mM 
EDTA (pH 6.5) with 6.6% SDS).  To quantify the amount of inorganic phosphate present in each sample, 
120 µL color developing solution (0.5% ammonium molybdate in 1 N H2SO4 with 18 mM ferrous 
sulfate) was added.  After incubating the samples at RT for 20 min, the absorbance of the sample at 700 
nm was measured.  The rate of phosphate release was calculated based on a phosphate standard curve.  
Enzymatic activity (s-1) was calculated using a molecular weight of 334,000 for HMM. 
 
Sliding Filament Assays 
 
Sliding filament assays were performed according to Sellers.[11]  To improve the quality of the actin 
filament movement, prior to each assay, myosin at 1 mg/mL in 0.5 M KCl, 10 mM MOPS (pH 7.0), 0.1 
mM EGTA, 5 mM MgCl2, 2 mM ATP, and 6 μM actin was centrifuged at 480,000  g for 7 min to 
remove myosin containing heads that bind actin but that do not hydrolyze ATP.  The supernatant was 
added at a concentration of about 0.2 mg/mL to a flow chamber constructed from a nitrocellulose-coated 
coverslip and microscope slide.  The flow chamber was then blocked with 3 volumes BSA (1 mg/mL) in 
0.5 M KCl, 10 mM MOPS (pH 7.0), and 0.1 mM EGTA and then washed with 3 volumes of motility 
buffer (20 mM MOPS (pH 7.4), 50 mM KCl, 4 mM MgCl2, and 0.1 mM EGTA).  Sheared actin (5 μM) 
with 1 mM ATP in motility buffer was added to block myosin heads that do not hydrolyze ATP, and the 
flow cell was washed with 3 volumes of motility buffer.  TRITC-phalloidin labeled F-actin (20 nM) in 
motility buffer was added, and the assay was started by the addition of assay buffer (motility buffer 
containing 1 mM ATP, 20 mM DTT, 0.7% methylcellulose, 2.5 mg/mL glucose, 0.1 mg/mL glucose 
oxidase, and 20 μg/mL catalase).  For native myosin phosphorylated by myosin light chain kinase, the 
wash containing sheared actin also contained 2 μg/mL myosin light chain kinase, 0.2 mM calmodulin, 
and 0.2 mM CaCl2.  Analysis of the uncaged myosin was performed by irradiating the protein in the 
presence of 5 mM DTT prior to its addition to the flow chamber.  While movement was observed if the 
flow chamber itself was irradiated, the quality of the images was compromised due to photobleaching of 
the TRITC-labeled actin during irradiation.  Filament movement was observed with a 100x objective on 
an Olympus IX50 microscope equipped with a Videoscope ICCD intensified CCD camera and recorded 
on a Panasonic VHS recorder.  Data was quantified using the Cell Tracker software from Motion 
Analysis and was analyzed according to Homsher, et al.[12] 
 
Cellular Experiments 
 
COS-7 cells were cultured in Dulbeco Modified Eagle’s Media supplemented with 10% fetal bovine 
serum at 37 C in a humidified environment with 5% CO2. For injection and imaging experiments, cells 
were transferred to custom-made, glass-bottom pertri dishes comprised of a No. 1.5 coverslip coated 
with 2 g/mL fibronectin overnight at 4 C. Microinjection needles were pulled from borosilicate glass 
micropipettes (inner diameter = 0.78 mm, outer diameter = 1.0 mm, with filament) using a Model PC 84 
Sachs-Flaming Micropipette puller. Micropipette tip size was estimated to be ~0.5 m.[13] To prevent the 
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needle from clogging, myosin at ~2.5 mg/mL in sterile PBS supplemented with 295 mM KCl, 0.5 mM 
DTT, and 1 mg/mL Texas Red-conjugated 10,000 MW lysine-fixable dextran was centrifuged at 75,000 
 g for 30 min at 4 C. The supernatant was then back-loaded into the micropipettes and injected into 
cells at a pressure of 0.8-1.8 psi using a Narishige IM 300 Microinjector mounted on a Nikon Diaphot 
microscope. To prevent inadvertent uncaging during injection, a glass UV filter (blocking < 400 nm 
light) and a red additive dichroic color filter (passing > 600 nm light) were placed in the trans-
illumination beam path, and cells were never exposed to arc lamp illumination. For injection, cells were 
maintained in culture media supplemented with 150 mM KCl to enhance myosin solubility and to 
prevent the needle from clogging. Post-injection, cells were returned to culture media and allowed to 
recover for 1-4 h. 
 
Uncaging was accomplished by exposing cells to the emission of a Stratagene 2020E transilluminator 
for 2 min.  Cells were allowed to recover for 20 min.  The cells were then fixed with 2% formaldehyde 
and permeabilized with 0.05% saponin. Cells were blocked with a solution of 2% BSA and 0.05% 
saponin and incubated with a rabbit phospho-specific mRLC antibody diluted 1:400 in blocking buffer.  
Cells were then blocked and stained with Alexa Fluor 647 goat anti-rabbit antibody diluted 1:400 in 
blocking buffer. PBS was used as the media during imaging experiments. Cells were imaged on a Nikon 
TE 300 Microscope equipped with a 100x TIRF lens and a HQ2 Cool Snap Camera. Texas Red-
conjugated dextran and Alexa Fluor 647 were imaged through standard filter sets with 500 ms exposures. 
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